Efficacy and tolerability of bevacizumab in patients with severe Covid-19
In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO2 ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving o...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/837c65e8b2da450bbaf3a3e72a7c8816 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:837c65e8b2da450bbaf3a3e72a7c8816 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:837c65e8b2da450bbaf3a3e72a7c88162021-12-02T10:44:05ZEfficacy and tolerability of bevacizumab in patients with severe Covid-1910.1038/s41467-021-21085-82041-1723https://doaj.org/article/837c65e8b2da450bbaf3a3e72a7c88162021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21085-8https://doaj.org/toc/2041-1723In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO2 ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.Jiaojiao PangFeng XuGianmarco AondioYu LiAlberto FumagalliMing LuGiuseppe ValmadreJie WeiYuan BianMargherita CanesiGiovanni DamianiYuan ZhangDexin YuJun ChenXiang JiWenhai SuiBailu WangShuo WuAttila KovacsMiriam ReveraHao WangXu JingYing ZhangYuguo ChenYihai CaoNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Jiaojiao Pang Feng Xu Gianmarco Aondio Yu Li Alberto Fumagalli Ming Lu Giuseppe Valmadre Jie Wei Yuan Bian Margherita Canesi Giovanni Damiani Yuan Zhang Dexin Yu Jun Chen Xiang Ji Wenhai Sui Bailu Wang Shuo Wu Attila Kovacs Miriam Revera Hao Wang Xu Jing Ying Zhang Yuguo Chen Yihai Cao Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |
| description |
In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO2 ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation. |
| format |
article |
| author |
Jiaojiao Pang Feng Xu Gianmarco Aondio Yu Li Alberto Fumagalli Ming Lu Giuseppe Valmadre Jie Wei Yuan Bian Margherita Canesi Giovanni Damiani Yuan Zhang Dexin Yu Jun Chen Xiang Ji Wenhai Sui Bailu Wang Shuo Wu Attila Kovacs Miriam Revera Hao Wang Xu Jing Ying Zhang Yuguo Chen Yihai Cao |
| author_facet |
Jiaojiao Pang Feng Xu Gianmarco Aondio Yu Li Alberto Fumagalli Ming Lu Giuseppe Valmadre Jie Wei Yuan Bian Margherita Canesi Giovanni Damiani Yuan Zhang Dexin Yu Jun Chen Xiang Ji Wenhai Sui Bailu Wang Shuo Wu Attila Kovacs Miriam Revera Hao Wang Xu Jing Ying Zhang Yuguo Chen Yihai Cao |
| author_sort |
Jiaojiao Pang |
| title |
Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |
| title_short |
Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |
| title_full |
Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |
| title_fullStr |
Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |
| title_full_unstemmed |
Efficacy and tolerability of bevacizumab in patients with severe Covid-19 |
| title_sort |
efficacy and tolerability of bevacizumab in patients with severe covid-19 |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/837c65e8b2da450bbaf3a3e72a7c8816 |
| work_keys_str_mv |
AT jiaojiaopang efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT fengxu efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT gianmarcoaondio efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT yuli efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT albertofumagalli efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT minglu efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT giuseppevalmadre efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT jiewei efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT yuanbian efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT margheritacanesi efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT giovannidamiani efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT yuanzhang efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT dexinyu efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT junchen efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT xiangji efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT wenhaisui efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT bailuwang efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT shuowu efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT attilakovacs efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT miriamrevera efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT haowang efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT xujing efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT yingzhang efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT yuguochen efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 AT yihaicao efficacyandtolerabilityofbevacizumabinpatientswithseverecovid19 |
| _version_ |
1718396836879794176 |